Anika Therapeutics, Inc.
ANIK Nasdaq
SEC CIK 898437
Follow Anika Therapeutics
Weekly email: filings, results
Revenue, last quarter
$30.6M
+10% vs same quarter last year
Net income
−$311K
+86.6% vs same quarter last year
EPS, diluted
−$0.02
+87.5% vs same quarter last year
Operating cash flow
$8.4M
+21.9% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $112.8M | −$11M |
| FY24 | $119.9M | −$56M |
| FY23 | $120.8M | −$83M |
| FY22 | $113.8M | −$15M |
| FY21 | $147.8M | $4M |
| FY20 | $130.5M | −$24M |
| FY19 | $114.6M | $27.2M |
| FY18 | $105.6M | $18.7M |
| FY17 | $113.4M | $31.8M |
| FY16 | $103.4M | $32.5M |
| FY15 | $93M | $30.8M |
| FY14 | $105.6M | $38.3M |
| FY13 | $75.1M | $20.6M |
| FY12 | $71.4M | $11.8M |
| FY11 | $64.8M | $8.5M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 56.6% | −9.8% | −9.8% |
| FY24 | 63.4% | −4.3% | −46.7% |
| FY23 | 68.3% | 0.7% | −68.7% |
| FY22 | 64.3% | 3.2% | −13.2% |
| FY21 | 56.1% | 1.8% | 2.7% |
| FY20 | 52.9% | −21.7% | −18.4% |
| FY19 | 74.9% | 29.9% | 23.7% |
| FY18 | 70.4% | 20.6% | 17.7% |
| FY17 | 75.9% | 40.3% | 28.1% |
| FY16 | 76.8% | 49% | 31.5% |
| FY15 | 77.4% | 51.8% | 33.1% |
| FY14 | 80.2% | 58.2% | 36.3% |
| FY13 | 69.7% | 43.4% | 27.4% |
| FY12 | 59.4% | 27.6% | 16.5% |
| FY11 | 58.7% | 21.6% | 13.1% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $4.4M |
| FY24 | −$2.3M |
| FY23 | −$7.2M |
| FY22 | −$3.1M |
| FY21 | $3.3M |
| FY20 | $11.4M |
| FY19 | $34.2M |
| FY18 | $30.3M |
| FY17 | $31.8M |
| FY16 | $10.4M |
| FY15 | $30.7M |
| FY14 | $38.4M |
| FY13 | $24.7M |
| FY12 | $9M |
| FY11 | $8.8M |
Show the numbers
| Year | Buybacks |
|---|---|
| FY25 | $9.5M |
| FY24 | $10.9M |
| FY23 | $5M |
| FY22 | $0 |
| FY21 | $0 |
| FY20 | $0 |
| FY19 | $30M |
| FY18 | $30M |
| FY17 | - |
| FY16 | $25M |
| FY15 | - |
| FY14 | - |
| FY13 | - |
| FY12 | - |
| FY11 | - |
- Anika Therapeutics
- Healthcare median
Show the numbers
| Year | Anika Therapeutics | Healthcare median |
|---|---|---|
| FY25 | −9.8% | −30.6% |
| FY24 | −46.7% | −47% |
| FY23 | −68.7% | −58% |
| FY22 | −13.2% | −80.4% |
| FY21 | 2.7% | −71.9% |
| FY20 | −18.4% | −62.2% |
| FY19 | 23.7% | −46.3% |
| FY18 | 17.7% | −49.6% |
| FY17 | 28.1% | −45.9% |
| FY16 | 31.5% | −36% |
| FY15 | 33.1% | −38.4% |
| FY14 | 36.3% | −35.5% |
| FY13 | 27.4% | −37.1% |
| FY12 | 16.5% | −29.1% |
| FY11 | 13.1% | −27.9% |